Detalhe da pesquisa
1.
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials.
Lancet
; 400(10351): 512-521, 2022 08 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35964611
2.
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
Invest New Drugs
; 39(6): 1577-1586, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34180036
3.
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report.
Lancet Oncol
; 21(2): e97-e103, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32007210
4.
Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials.
Cancer Sci
; 109(1): 207-214, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29114963
5.
A Phase I Study of Ganetespib and Ziv-Aflibercept in Patients with Advanced Carcinomas and Sarcomas.
Oncologist
; 23(11): 1269-e125, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29853657
6.
Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials.
Breast Cancer Res Treat
; 168(1): 35-41, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29119354
7.
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.
Invest New Drugs
; 36(2): 230-239, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28808818
8.
Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials.
Gastric Cancer
; 20(3): 481-488, 2017 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-27510411
9.
Compressing drug development timelines in oncology using phase '0' trials.
Nat Rev Cancer
; 7(2): 131-9, 2007 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-17251919
10.
Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.
Invest New Drugs
; 33(3): 720-8, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25637165
11.
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.
JCO Precis Oncol
; 8: e2300407, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38603650
12.
Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.
JCO Precis Oncol
; 8: e2300406, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38603651
13.
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
Clin Cancer Res
; 30(7): 1273-1280, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38433347
14.
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
JCO Precis Oncol
; 8: e2300454, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38591867
15.
Racial differences in longitudinal toxicities of anticancer agents in early phase cancer clinical trials.
Cancer Med
; 12(17): 18098-18109, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37519123
16.
COVID-19 severity by vaccination status in the NCI COVID-19 and Cancer Patients Study (NCCAPS).
J Natl Cancer Inst
; 115(5): 597-600, 2023 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36702472
17.
Expanding access to early phase trials: the CATCH-UP.2020 experience.
JNCI Cancer Spectr
; 7(1)2023 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36525371
18.
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B.
Clin Cancer Res
; 29(8): 1477-1483, 2023 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36853016
19.
The NCI-MATCH trial: lessons for precision oncology.
Nat Med
; 29(6): 1349-1357, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37322121
20.
A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials.
Clin Trials
; 9(4): 385-95, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22811448